Venus Medtech (Hangzhou), Inc. Class H (HK:2500) has released an update.
Venus Medtech (Hangzhou) Inc. has engaged Deloitte Advisory to conduct a review of the historical use of its equity fundraising proceeds to determine if they were used for unauthorized transactions. A report from the review was submitted to and approved by the company’s Special Committee and Board on September 2, 2024. This announcement comes in the context of ongoing trading suspension and efforts towards resumption.
For further insights into HK:2500 stock, check out TipRanks’ Stock Analysis page.
